Roskamp Research LLC
Records under this name other than patents Roskamp Research LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Roskamp Research LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,732,467 | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,067,372 | Modulation of angiogenesis by A-beta peptide fragments Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,236,346 | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer Formerly held Lapsed on the fee record Ended Aug 7, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 7, 2024 | From the USPTO record |
| US 8,236,347 | Pharmaceutical compositions for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis Formerly held Lapsed on the fee record Ended Aug 7, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 7, 2024 | From the USPTO record |
| US 7,589,168 | Inhibition of Angiogenesis by A-Beta Peptides Formerly held Lapsed on the fee record Ended Sep 15, 2021 · High confidence | Lapsed on the fee record | Ended Sep 15, 2021 | High confidence |
| US 6,011,019 | Vasoactive effects and free radical generation by .beta.-amyloid peptides Formerly held Term ended Term ended Nov 12, 2016 · From the USPTO record | Term ended | Term ended Nov 12, 2016 | From the USPTO record |
| US 6,787,318 | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology Formerly held Lapsed on the fee record Ended Sep 7, 2016 · From the USPTO record | Lapsed on the fee record | Ended Sep 7, 2016 | From the USPTO record |
| US 7,052,852 | CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease Formerly held Lapsed on the fee record Ended May 30, 2014 · From the USPTO record | Lapsed on the fee record | Ended May 30, 2014 | From the USPTO record |
| US 7,605,149 | Modulation of the phospholipase A2 pathway as a therapeutic Formerly held Lapsed on the fee record Ended Oct 20, 2013 · From the USPTO record | Lapsed on the fee record | Ended Oct 20, 2013 | From the USPTO record |
| US 6,140,309 | Vasoactive effects and free radical generation by .beta.-amyloid peptides Formerly held Lapsed on the fee record Ended Oct 31, 2012 · From the USPTO record | Lapsed on the fee record | Ended Oct 31, 2012 | From the USPTO record |